CRISPR Therapeutics AG (NASDAQ: CRSP)’s stock price has soared by 6.61% in relation to previous closing price of $51.19. Nevertheless, the company has seen a gain of 12.20% in its stock price over the last five trading days. fool.com reported 2025-07-08 that When picking new stocks for your portfolio, your best bet is looking for companies that you can hold forever. It may take that long for an idea or a business premise to fully pay off!
Is It Worth Investing in CRISPR Therapeutics AG (NASDAQ: CRSP) Right Now?
The 36-month beta value for CRSP is also noteworthy at 1.79. There are mixed opinions on the stock, with 12 analysts rating it as a “buy”, 5 rating it as “overweight”, 10 rating it as “hold”, and 1 rating it as “sell”.
The public float for CRSP is 82.79M, and at present, short sellers hold a 25.86% of that float. The average trading volume of CRSP on July 08, 2025 was 2.60M shares.
CRSP’s Market Performance
CRSP’s stock has seen a 12.20% increase for the week, with a 41.50% rise in the past month and a 67.15% gain in the past quarter. The volatility ratio for the week is 6.80%, and the volatility levels for the past 30 days are at 5.79% for CRISPR Therapeutics AG The simple moving average for the last 20 days is 18.18% for CRSP’s stock, with a simple moving average of 26.18% for the last 200 days.
Analysts’ Opinion of CRSP
Many brokerage firms have already submitted their reports for CRSP stocks, with Evercore ISI repeating the rating for CRSP by listing it as a “Outperform”. The predicted price for CRSP in the upcoming period, according to Evercore ISI is $99 based on the research report published on February 14, 2025 of the current year 2025.
TD Cowen, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $35. The rating they have provided for CRSP stocks is “Hold” according to the report published on February 12th, 2025.
Needham gave a rating of “Buy” to CRSP, setting the target price at $84 in the report published on August 06th of the previous year.
CRSP Trading at 33.45% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.30% of loss for the given period.
Volatility was left at 5.79%, however, over the last 30 days, the volatility rate increased by 6.80%, as shares surge +29.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.69% upper at present.
During the last 5 trading sessions, CRSP rose by +11.52%, which changed the moving average for the period of 200-days by +8.77% in comparison to the 20-day moving average, which settled at $46.16. In addition, CRISPR Therapeutics AG saw 1.25% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRSP starting from Patel Naimish, who sold 3,932 shares at the price of $35.94 back on May 29 ’25. After this action, Patel Naimish now owns 6,068 shares of CRISPR Therapeutics AG, valued at $141,316 using the latest closing price.
Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 10,031 shares at $41.23 during a trade that took place back on Mar 21 ’25, which means that Kulkarni Samarth is holding 195,085 shares at $413,578 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -12.83% for the present operating margin
- -2.4% for the gross margin
The net margin for CRISPR Therapeutics AG stands at -10.43%. The total capital return value is set at -0.23%. Equity return is now at value -19.71%, with -16.75% for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4.
Currently, EBITDA for the company is -447.31 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 127.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.64.
Conclusion
In summary, CRISPR Therapeutics AG (CRSP) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
